- Home
- AZ vs OBIO Comparison
AZ vs OBIO Comparison
Compare AZ & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | OBIO |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.6M | 253.9M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AZ | OBIO |
|---|---|---|
| Price | $6.92 | $5.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $15.00 | $14.25 |
| AVG Volume (30 Days) | ★ 553.8K | 285.5K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | $532.60 | N/A |
| Revenue Next Year | $178.94 | $12.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $4.97 | $2.20 |
| 52 Week High | $9.82 | $5.78 |
Technical Indicators
Market Signals| Indicator | AZ | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 65.78 |
| Support Level | $6.57 | $4.07 |
| Resistance Level | $6.99 | $5.42 |
| Average True Range (ATR) | 0.59 | 0.29 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 41.09 | 66.46 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.